Overview

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: A peripheral stem cell transplant or bone marrow transplant from a brother or sister may be an effective treatment for kidney cancer. PURPOSE: This phase II trial is studying how well a donor peripheral stem cell or bone marrow transplant works in treating patients with relapsed or refractory metastatic kidney cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Rochester
Treatments:
Antilymphocyte Serum
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Criteria
DISEASE CHARACTERISTICS:

- Histologically confirmed metastatic renal cell carcinoma

- Relapsed or refractory disease

- Tumor not amenable to complete surgical resection

- No bone metastases only

- No untreated brain metastases

- Measurable disease

- Available sibling donor who is HLA-identical or who has a mismatch at a single HLA
locus (i.e., a 6/6 or 5/6 match at the HLA-A, -B, and -DR loci)

PATIENT CHARACTERISTICS:

Performance status

- ECOG 0-2

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Bilirubin < 3 mg/dL

Renal

- Creatinine < 2 mg/dL

- No untreated hypercalcemia

Cardiovascular

- LVEF ≥ 40%

Pulmonary

- DLCO ≥ 40%

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Negative pregnancy test

- HIV-1 and -2 negative

- No uncontrolled infection

- No other active malignancy except basal skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

- At least 15 days since prior treatment for renal cell carcinoma

- No other concurrent anticancer therapy